Tibsovo (Ivosidenib) is an isocitrate dehydrogenase-1 (IDH1) inhibitor used to treat adults with newly-diagnosed acute myeloid leukemia (AML) who are aged ≥ 75 years old, and adult patients with relapsed or refractory acute myeloid leukemia (AML).
Dosage: The recommended dose of ivosidenib is 500 mg administered orally once daily until the disease is progressive or in occurrence of unacceptable toxicity. Administer the dose of ivosidenib 500 mg with or without food. It is not advised to administer the pills with a high fat meal due to an increase in the ivosidenib concentration. Do not split or crush ivosidenib tablets. Administer the ivosidenib tablets by mouth at around the same time every day. If any dose of ivosidenib is vomited, patients are advised to avoid administering a replacement dose and wait until the upcoming scheduled dose is due. If an ivosidenib dose is missed or not administered at about the usual schedule, administer that dose promptly and at least 12 hours before the next scheduled dose. Return to the normal dosing schedule the following day. Strictly avoid administering 2 doses within 12 hours.
Side Effects: The most commonly reported ivosidenib side effects may include:
- Decreased appetite
- Electrocardiogram QT prolonged
Warnings and Precautions:
- Patients with therapy ivosidenib 250 mg should be monitored for electrolytes and electrocardiograms (ECGs). Monitor patients taking ivosidenib 500 mg for onset of new signs/symptoms of motor and sensory neuropathy.
- The use of tibsovo 500 mg may cause fertility complications in females and males, which may affect their ability to have children.
- Nursing women are advised not to breastfeed while on ivosidenib dosage and for at least 1 month following the last dose.
- Use of tibsovo tablets could be responsible for causing harm to fetus. Patients are advised to avoid conceiving a baby while on treatment with it.
- Blood tests of respective patients should be done prior to initiating and during treatment with tibsovo 250 mg.